The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: A clinical observational study

Journal of Cardiovascular Magnetic Resonance

Volumn 11, Issue 1, 2009, Pages

  Berdoukas, Vasilios ^a   Chouliaras, Giorgos ^a   Moraitis, Panagiotis ^a   Zannikos, Kirykos ^a   Berdoussi, Eleni ^a   Ladis, Vassilios ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; IRON; IRON CHELATING AGENT; PYRIDONE DERIVATIVE;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CLINICAL STUDY; DRUG EFFICACY; FEMALE; HEART; HUMAN; IRON CHELATION; LIVER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THALASSEMIA MAJOR; TREATMENT DURATION; BETA THALASSEMIA; DRUG COMBINATION; DRUG EFFECT; HEART MUSCLE; HOSPITALIZATION; METABOLISM; PATHOLOGY; STATISTICAL MODEL; TIME; TREATMENT OUTCOME;

ADULT; BETA-THALASSEMIA; DEFEROXAMINE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IRON; IRON CHELATING AGENTS; LIVER; LOGISTIC MODELS; MAGNETIC RESONANCE IMAGING; MALE; MYOCARDIUM; PYRIDONES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 70349567584     PISSN: 10976647     EISSN: 1532429X     Source Type: Journal    
DOI: 10.1186/1532-429X-11-20     Document Type: Article

References (42)

1. Longitudinal study of survival and causes of death in patients with thalassemia major in Greece. V Ladis G Chouliaras H Berdousi E Kanavakis C Kattamis, Ann N Y Acad Sci 2005 1054 445 450 10.1196/annals.1345.067 16339695
2. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. C Borgna-Pignatti S Rugolotto P De Stefano H Zhao MD Cappellini GC Del Vecchio MA Romeo GL Forni MR Gamberini R Ghilardi,, et al. Haematologica 2004 89 1187 1193 15477202
3. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. B Modell M Khan M Darlison, Lancet 2000 355 2051 2052 10.1016/S0140-6736(00)02357-6 10885361
4. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. B Modell M Khan M Darlison MA Westwood D Ingram DJ Pennell, J Cardiovasc Magn Reson 2008 10 42 18817553 10.1186/1532-429X-10-42
5. Impact of thalassemia major on patients and their families. JJ Caro A Ward TC Green K Huybrechts A Arana S Wait A Eleftheriou, Acta Haematol 2002 107 150 157 10.1159/000057633 11978936
6. Cardiac status in well-treated patients with thalassemia major. A Aessopos D Farmakis A Hatziliami C Fragodimitri F Karabatsos J Joussef E Mitilineou E Diamanti-Kandaraki J Meletis M Karagiorga, Eur J Haematol 2004 73 359 366 10.1111/j.1600-0609.2004.00304.x 15458515
7. Lack of correlation between iron overload cardiac dysfunction and needle liver biopsy iron concentration. V Berdoukas C Dakin A Freeman I Fraser A Aessopos T Bohane, Haematologica 2005 90 685 686 15921384
8. Myocardial iron loading in patients with thalassemia major on deferoxamine chelation. MA Tanner R Galanello C Dessi MA Westwood GC Smith SV Nair LJ Anderson JM Walker DJ Pennell, J Cardiovasc Magn Reson 2006 8 543 547 10.1080/10976640600698155 16755844
9. Cardiac magnetic resonance imaging R2* assessments and analysis of historical parameters in patients with transfusion-dependent thalassemia. A Aessopos C Fragodimitri F Karabatsos A Hatziliami J Yousef A Giakoumis A Dokou ED Gotsis V Berdoukas M Karagiorga, Haematologica 2007 92 131 132 10.3324/haematol.10455 17229649
10. Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. JC Wood JM Tyszka S Carson MD Nelson TD Coates, Blood 2004 103 1934 1936 10.1182/blood-2003-06-1919 14630822
11. Hepatic iron concentration and total body iron stores in thalassemia major. E Angelucci GM Brittenham CE McLaren M Ripalti D Baronciani C Giardini M Galimberti P Polchi G Lucarelli, N Engl J Med 2000 343 327 331 10.1056/NEJM200008033430503 10922422
12. Hepatocellular carcinoma in the thalassaemia syndromes. C Borgna-Pignatti G Vergine T Lombardo MD Cappellini P Cianciulli A Maggio D Renda ME Lai A Mandas G Forni,, et al. Br J Haematol 2004 124 114 117 10.1046/j.1365-2141.2003. 04732.x 14675416
13. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. LJ Anderson S Holden B Davis E Prescott CC Charrier NH Bunce DN Firmin B Wonke J Porter JM Walker DJ Pennell, Eur Heart J 2001 22 2171 2179 10.1053/euhj.2001.2822 11913479
14. Iron chelation treatment with combined therapy with deferiprone and deferioxamine: a 12-month trial. A Kattamis V Ladis H Berdousi NL Kelekis E Alexopoulou I Papasotiriou K Drakaki I Kaloumenou A Galani C Kattamis, Blood Cells Mol Dis 2006 36 21 25 10.1016/j.bcmd.2005.11.002 16386928
15. Intercentre reproducibility of magnetic resonance T2* measurements of myocardial iron in thalassaemia. MA Westwood DN Firmin M Gildo G Renzo G Stathis K Markissia B Vasili DJ Pennell, Int J Cardiovasc Imaging 2005 21 531 538 10.1007/s10554-005-0651-2 16175443
16. Cardiac iron determines cardiac T2*, T2, and T1 in the gerbil model of iron cardiomyopathy. JC Wood M Otto-Duessel M Aguilar H Nick MD Nelson TD Coates H Pollack R Moats, Circulation 2005 112 535 543 10.1161/CIRCULATIONAHA. 104.504415 16027257
17. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. JC Wood C Enriquez N Ghugre JM Tyzka S Carson MD Nelson TD Coates, Blood 2005 106 1460 1465 15860670 10.1182/blood-2004-10-3982
18. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. DJ Pennell V Berdoukas M Karagiorga V Ladis A Piga A Aessopos ED Gotsis MA Tanner GC Smith MA Westwood,, et al. Blood 2006 107 3738 3744 10.1182/blood-2005-07- 2948 16352815
19. Longitudinal analysis of heart and liver iron in thalassemia major. LJ Noetzli SM Carson AS Nord TD Coates JC Wood, Blood 2008 112 2973 2978 10.1182/blood-2008-04-148767 18650452
20. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. LJ Anderson MA Westwood S Holden B Davis E Prescott B Wonke JB Porter JM Walker DJ Pennell, Br J Haematol 2004 127 348 355 10.1111/j.1365-2141.2004.05202.x 15491298
21. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. C Borgna-Pignatti MD Cappellini P De Stefano GC Del Vecchio GL Forni MR Gamberini R Ghilardi A Piga MA Romeo H Zhao A Cnaan, Blood 2006 107 3733 3737 10.1182/blood-2005-07-2933 16373663
22. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. A Piga C Gaglioti E Fogliacco F Tricta, Haematologica 2003 88 489 496 12745268
23. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. MA Tanner R Galanello C Dessi GC Smith MA Westwood A Agus M Roughton R Assomull SV Nair JM Walker DJ Pennell, Circulation 2007 115 1876 1884 10.1161/CIRCULATIONAHA.106.648790 17372174
24. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. MA Tanner R Galanello C Dessi GC Smith MA Westwood A Agus M Pibiri SV Nair JM Walker DJ Pennell, J Cardiovasc Magn Reson 2008 10 12 18298856 10.1186/1532-429X-10-12
25. Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major. KH Wu JS Chang CH Tsai CT Peng, Ann Hematol 2004 83 471 473 10.1007/s00277-003-0820-0 14658011
26. Reversal of heart failure in thalassemia major by combined chelation therapy: a case report. M Tsironi S Deftereos P Andriopoulos D Farmakis J Meletis A Aessopos, Eur J Haematol 2005 74 84 85 10.1111/j.1600-0609.2004.00335. x 15613114
27. Successful recovery of acute hemosiderotic heart failure in beta-thalassemia major treated with a combined regimen of desferrioxamine and deferiprone. L Tavecchia N Masera P Russo A Ciro A Vincenzi C Vimercati G Masera, Haematologica 2006 91 CR19 16785138
28. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. BA Davis JB Porter, Blood 2000 95 1229 1236 10666195
29. Reversal of cardiac complications in thalassemia major by long-term intermittent daily intensive iron chelation. H Miskin I Yaniv M Berant C Hershko H Tamary, Eur J Haematol 2003 70 398 403 10.1034/j.1600-0609.2003.00075.x 12756023
30. Efficacy and safety of deferasirox (Exjade) in reducing cardiac iron in patients with -thalassemia major: Results from the cardiac substudy of the EPIC trial. DJ Pennell JB Porter MD Cappellini C-K Li Y Aydinok LL Chan A Kattamis G Smith D Habr G Domokos A Hmissi A Taher, ASH Annual Meeting, San Francisco, USA, 6-9 December 2008
31. Response of myocardial T2* to oral deferasirox monotherapy for 1 year in 29 patients with transfusion-dependent anaemias; A subgroup analysis. P Eleftheriou M Tanner D Pennell J Porter, Haematologica 2006 91 Suppl 1 bst 999
32. Deferasirox (Exjade) monotherapy significantly reduces cardiac iron burden in chronically transfused -thalassemia patients: An MRI T2* study. J Wood A Thompson C Paley B Kang P Giardina P Harmatz J Virkus T Coates, ASH Annual Meeting, San Francisco, USA, 6-9 December 2008
33. Impact of Compliance, Ferritin and LIC on Long-Term Trends in Myocardial T2* with Deferasirox. M Garbowski P Eleftheriou D Pennell M Tanner JB Porter, ASH Annual Meeting San Francisco: Blood 2008 112 49 50
34. Comparison of deferasirox, deferiprone and desferrioxamine effectiveness on myocardial iron concenrations and biventricular function by quantitative MRI in thalassemia major. A Pepe B Favilli V Positano P Cianciulli A Spasiano M Capra C Borgna-Pigniatti MC Putti T Casini MA Romeo MG Bisconte A Filosa V Caruso A Quarta L Pitrolo V De Sanctis C Gerardi C Maggio A Pietrangelo M Lombardi, ASH Annual Meeting, San Francisco, USA, 6-9 December 2008
35. Measurement and mapping of liver iron concentrations using magnetic resonance imaging. TG St Pierre PR Clark W Chua-Anusorn, Ann N Y Acad Sci 2005 1054 379 385 10.1196/annals.1345.046 16339686
36. Liver iron concentration and fibrosis in a cohort of transfusion- dependent patients on long-term desferrioxamine therapy. V Berdoukas T Bohane V Tobias K De Silva I Fraser A Aessopos R Lindeman, Hematol J 2005 5 572 578 10.1038/sj.thj.6200569 15692602
37. Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients. SF Wu CT Peng KH Wu CH Tsai, Hemoglobin 2006 30 215 218 10.1080/03630260600642534 16798646
38. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. MD Cappellini A Cohen A Piga M Bejaoui S Perrotta L Agaoglu Y Aydinok A Kattamis Y Kilinc J Porter,, et al. Blood 2006 107 3455 3462 10.1182/blood-2005-08-3430 16352812
39. Optimising chelation therapy: Combining deferiprone and deferoxamine. R Grady V Berdoukas EA Rachmielewitz PJ Giardina, Blood 2000 96 604
40. Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major. AR Cohen E Glimm JB Porter, Blood 2008 111 583 587 10.1182/blood-2007-08-109306 17951527
41. B Modell V Berdoukas, The Clinical Approach to Thalassaemia New York: Grune & Stratton 1 1984
42. Combined therapy with deferiprone and desferrioxamine. B Wonke C Wright AV Hoffbrand, Br J Haematol 1998 103 361 364 10.1046/j.1365-2141.1998.01002.x 9827905